Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Medicenna Therapeutics Corp (MDNAF)

Medicenna Therapeutics Corp (MDNAF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 96,795
  • Shares Outstanding, K 69,637
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,600 K
  • 60-Month Beta 2.11
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.63
Trade MDNAF with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.18
  • Most Recent Earnings $-0.05 on 02/14/24
  • Latest Earnings Date 02/20/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.05
  • Number of Estimates 1
  • High Estimate -0.05
  • Low Estimate -0.05
  • Prior Year -0.04
  • Growth Rate Est. (year over year) -25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0306 +35.84%
on 04/09/24
1.5600 -10.26%
on 03/28/24
+0.2823 (+25.26%)
since 03/25/24
3-Month
0.3030 +362.05%
on 02/01/24
1.5600 -10.26%
on 03/28/24
+1.0622 (+314.45%)
since 01/25/24
52-Week
0.1513 +825.31%
on 11/01/23
1.5600 -10.26%
on 03/28/24
+0.7400 (+112.12%)
since 04/25/23

Most Recent Stories

More News
Medicenna to Present at the Bloom Burton & Co. Healthcare Investor Conference

TORONTO and HOUSTON, April 14, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...

MDNAF : 1.4000 (+0.72%)
MDNA.TO : 1.95 (+1.56%)
MDNA : 0.1570 (-13.16%)
Medicenna Presents Preclinical Data Demonstrating Potent Immune Modulating Effects of an IL-2/IL-13 Dual Specific Cytokine at the 2021 AACR Annual Meeting

-- The IL-2/IL-13 dual specific cytokine selectively stimulates anti-cancer immune cells and inhibits M2a polarization of pro-tumoral macrophages

MDNAF : 1.4000 (+0.72%)
MDNA.TO : 1.95 (+1.56%)
MDNA : 0.1570 (-13.16%)
Medicenna Announces Preclinical Data on MDNA11 with Anti-PD-1 Therapy and Unveils Novel Bifunctional Superkines at the Cytokine-Based Cancer Immunotherapies Summit

-- MDNA11 and anti-PD-1 combination leads to complete responses in a murine solid tumor model

MDNAF : 1.4000 (+0.72%)
MDNA.TO : 1.95 (+1.56%)
MDNA : 0.1570 (-13.16%)
Medicenna Therapeutics Announces Upcoming Presentation at the AACR Annual Meeting 2021

TORONTO and HOUSTON, March 11, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...

MDNAF : 1.4000 (+0.72%)
MDNA.TO : 1.95 (+1.56%)
MDNA : 0.1570 (-13.16%)
Medicenna Therapeutics to Present at Upcoming March Investor Conferences

TORONTO and HOUSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...

MDNAF : 1.4000 (+0.72%)
MDNA.TO : 1.95 (+1.56%)
MDNA : 0.1570 (-13.16%)
Medicenna to Present at the Cowen 41st Annual Healthcare Conference

TORONTO and HOUSTON, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...

MDNAF : 1.4000 (+0.72%)
MDNA.TO : 1.95 (+1.56%)
MDNA : 0.1570 (-13.16%)
Medicenna to Present at the 10th Annual SVB Leerink Global Healthcare Conference

TORONTO and HOUSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...

MDNAF : 1.4000 (+0.72%)
MDNA.TO : 1.95 (+1.56%)
MDNA : 0.1570 (-13.16%)
Medicenna Reports Third Quarter Fiscal 2021 Financial Results and Operational Highlights

TORONTO and HOUSTON, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “Company") (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, today announced its...

MDNAF : 1.4000 (+0.72%)
MDNA.TO : 1.95 (+1.56%)
MDNA : 0.1570 (-13.16%)
Medicenna Establishes At-the-Market Sales Facility

TORONTO and HOUSTON, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, announced...

MDNAF : 1.4000 (+0.72%)
MDNA.TO : 1.95 (+1.56%)
MDNA : 0.1570 (-13.16%)
Medicenna Announces Oral Presentation at the 2nd Annual Glioblastoma Drug Development Summit

- Presentation taking place today , December 9 , 2020 at 10:50 AM ET

MDNAF : 1.4000 (+0.72%)
MDNA.TO : 1.95 (+1.56%)
MDNA : 0.1570 (-13.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Medicenna Therapeutics Corp is a clinical stage immuno-oncology company. It is engaged in developing engineered versions of IL-2, IL4 and IL13 cytokines called Superkines and Empowered Cytokines ECs for the treatment of cancer. Medicenna Therapeutics Corp is based in Toronto, Canada.

See More

Key Turning Points

3rd Resistance Point 1.7292
2nd Resistance Point 1.5645
1st Resistance Point 1.4773
Last Price 1.4000
1st Support Level 1.2254
2nd Support Level 1.0607
3rd Support Level 0.9735

See More

52-Week High 1.5600
Last Price 1.4000
Fibonacci 61.8% 1.0219
Fibonacci 50% 0.8556
Fibonacci 38.2% 0.6894
52-Week Low 0.1513

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar